A distinctive bullous skin reaction associated with enfortumab vedotin-ejfv treatment for metastatic urothelial cancer: A case report

J Dtsch Dermatol Ges. 2021 Dec;19(12):1781-1783. doi: 10.1111/ddg.14617. Epub 2021 Nov 16.

Authors

Torben Krause¹, Hanna Bonnekoh^{1

2}, Amrei Dilling¹, Alexander Nast¹, Martin Metz^{1

2}

Affiliations

¹ Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
² Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany.

PMID: 34786831
DOI: 10.1111/ddg.14617

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal* / adverse effects
Carcinoma, Transitional Cell* / drug therapy
Humans

Substances

Antibodies, Monoclonal
enfortumab vedotin